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phone: 905-387-9495, extension 64902; FAX:Purpose: Neoadjuvant chemotherapy and pelvic surgery are significant risk
factors for thromboembolic events. Our study objectives were to investigate the
timing, incidence and characteristics of thromboembolic events during and after
neoadjuvant chemotherapy and subsequent radical cystectomy in patients with
muscle invasive bladder cancer.
Materials and Methods: We performed a multi-institutional retrospective
analysis of 761 patients who underwent neoadjuvant chemotherapy and radical
cystectomy for muscle invasive bladder cancer from 2002 to 2014. Median fol-
lowup from diagnosis was 21.4 months (range 3 to 272). Patient characteristics
included the Khorana score, and the incidence and timing of thromboembolic
events (before vs after radical cystectomy). Survival was calculated using the
Kaplan-Meier method. The log rank test and multivariable Cox proportional
hazards regression were used to compare survival between patients with vs
without thromboembolic events.
Results: The Khorana score indicated an intermediate thromboembolic event
risk in 88% of patients. The overall incidence of thromboembolic events in pa-
tients undergoing neoadjuvant chemotherapy was 14% with a wide variation of
5% to 32% among institutions. Patients with thromboembolic events were older
(67.6 vs 64.6 years, p ¼ 0.02) and received a longer neoadjuvant chemotherapy
course (10.9 vs 9.7 weeks, p ¼ 0.01) compared to patients without a thrombo-
embolic event. Of the thromboembolic events 58% developed preoperatively and
72% were symptomatic. On multivariable regression analysis the development of
a thromboembolic event was not significantly associated with decreased overall
survival. However, pathological stage and a high Khorana score were adverse
risk factors for overall survival.
Conclusions: Thromboembolic events are common in patients with muscle
invasive bladder cancer who undergo neoadjuvant chemotherapy before and
after radical cystectomy. Our results suggest that a prospective trial of throm-
boembolic event prophylaxis during neoadjuvant chemotherapy is warranted.905-381-7071; e-mail: pinthusj@hhsc.ca).
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drug therapyLEVEL I evidence suggests that platinum based NAC
in combination with RC is associated with a signif-
icant survival advantage in patients with MIBC
compared to RC alone.1 This patient population is at
risk for TEEs for several reasons. The risk of a TEE
is increased as much as 70-fold in patients with
cancer in general,2e4 likely due to the malignancy
induced hypercoagulable state5 and immobiliza-
tion.6,7 In the particular population under study the
TEE risk is further compounded by NAC, especially
platinum based chemotherapy,8 as well as pelvic
surgery.9 In a Danish population based study the
risk of venous thromboembolism in patients with
bladder cancer within 3 months of diagnosis was
70-fold higher than in the general population with a
particularly high risk after RC.2 A meta-analysis of
24,861 patients with bladder cancer documented a
1-year 5.3 standardized incidence ratio for venous
thromboembolism compared with that of the gen-
eral population.10
While guidelines exist that support prolonged
postoperative TEE prophylaxis in surgical patients
with cancer who undergo abdominal or pelvic sur-
gery,9 to our knowledge there are currently no
guidelines or practice recommendations related to
TEE prophylaxis in patients with MIBC during the
NAC treatment course. Guidelines for patients with
cancer in general also do not include recommenda-
tions on thromboprophylaxis during chemo-
therapy.11 This is probably due to limited data
related to the incidence and natural history of TEE
in this patient population.
Our initial study based on data from McMaster
University showed an overall TEE incidence of 8.4%
in all 202 patients undergoing RC, which increased
to 19.1% in patients treated with both NAC and
RC.12 The objectives of the current study were to
investigate the incidence, characteristics and im-
plications of TEE during and after NAC and sub-
sequent RC for MIBC in a multi-institutional
retrospective study. We present data that indicate a
high incidence of TEE at the time of NAC admin-
istration when no standard TEE prophylaxis is
practiced, as well as postoperatively.MATERIALS AND METHODS
Patient Population
The study was approved at the lead institution (McMaster
University, Juravinski Hospital) by the Hamilton Inte-
grated Research Ethics Board under study number 12-243-
C as well as by institutional review boards at all othercenters. Ten tertiary centers, including 3 each in Canada
and Europe, and 4 in the United States, were approached
to identify patients who underwent NAC and subsequent
RC for MIBC from 2002 to 2014. The 21 patients already
on anticoagulant medication were excluded from study.
The incidence of TEE was the primary end point of this
study. A TEE was defined as a venous, arterial or central
venous port site thrombosis, or DVT, stroke or PE. The
incidence of TEE was determined retrospectively in 761
consecutive patients. The timing of TEEwasmeasured from
the start of NAC and categorized as preoperative (before
RC), early postoperative (within 1 month after RC) or late
postoperative (within 6 months after RC). If more than 1
TEE developed, the time and type of the first event were
used for analysis. TEEs were classified as clinical (symp-
tomatic) or incidental (detected by imaging performed for
unrelated reasons, such as CT for staging). Postoperative
prophylaxis was administered in the more contemporary
patients in the study. However, type and duration varied
across institutions, ranging from warfarin, Fragmin
(dalteparin), or unfractionated or low molecular weight
heparin for the duration of hospitalization to up to 6 weeks
postoperatively. Those data were not specifically captured.
The Khorana score, which was established to assess
the risk of TEE in patients with cancer treated with
chemotherapy, was determined prior to NAC in all pa-
tients. The Khorana score is based on baseline hemoglo-
bin, platelet and leukocyte counts as well as on body mass
index and tumor site.13 Other patient characteristics for
which data were collected included age, gender, anti-
platelet and anticoagulant medication use, history of prior
TEE, type and duration of NAC, histology, pathological
stage, complete response after NAC (pT0N0), disease
progression and survival.
Statistical Analysis
Categorical and continuous variables were compared
between patients with and without a TEE using the chi-
square test and the Wilcoxon rank sum test, respectively.
Kaplan-Meier survival curves and the log rank test were
used to compare survival between patients in whom TEE
did and did not develop. Multivariable Cox proportional
hazards regression was used to determine the HR and 95%
CI of cancer specific and overall survival, and assess the
association between TEE development and these outcomes
after adjusting for age, Khorana score and pathological
stage. Statistical analyses were performed using SPSS,
version 23 with p <0.05 considered significant.RESULTS
At 10 tertiary centers across North America and
Europe a total of 761 patients were identified who
underwent NAC and subsequent RC for MIBC.
Median followup from MIBC diagnosis was 21.4
months (range 3 to 272) in all patients and 25.6
THROMBOEMBOLIC EVENTS AND UROTHELIAL CANCER OF BLADDER 1629months (range 3 to 272) in survivors. Table 1 lists
patient characteristics stratified by TEE status.
One TEE developed in 101 patients each and 2
TEEs, separated in time, developed in 4 each. The
incidence of any TEE across the 10 institutions was
13.8% (fig. 1, A). Of the TEEs 71.6% were detected
clinically whereas 28.4% were detected incidentally
by imaging performed for unrelated reasons, most
commonly chest CT for restaging. Of the 99 TEEs for
which the type of TEE was known 49 (49.5%) were
DVT and 33 (33.3%) were PE while 4 patients pre-
sented with a DVT and PE simultaneously. Seven
TEEs presented as arterial emboli, 6 were port site
thromboses, of which 1 was fatal, and none of the
patients experienced a stroke. Of the 99 TEEs for
which the timing of the TEE was known 57 (57.6%)
occurred before RC, 19 (19.2%) occurred within 1
month of RC and 27 (27.3%) occurred between 1 and 6
months followingRC (fig. 1,B). The typeand timing of
the TEE was not available for 6 patients. Also, we
observed a broad, statistically significant 5.4% to
32.1% variation in TEE incidence among the 10 in-
stitutions (p <0.001). Figure 2 shows the cumulative
hazard plot of TEE occurrence with time.
Patients in whom a TEE developed were on
average older (age 67.6 vs 64.6 years, p ¼ 0.02) and
had longer NAC courses (10.9 vs 9.7 weeks,Table 1. Patient characteristics
NonTEE
Total No. pts 656
Preop
Median age at diagnosis (IQR)/761 pts 64.6 (57.3e71.3)
No. gender (%)/761 pts:
M 494 (75.3)
F 162 (24.7)
No. Khorana score (%)/594 pts:
1 315 (62.8)
2 129 (25.8)
3 51 (10.2)
4 6 (1.2)
No. antiplatelet medication (%)/594 pts 92 (18)
Median wks NAC (IQR)/614 pts 9.7 (7.0e12.0)
No. NAC cycles (%)/710 pts:
1e3 267 (43.6)
4e8 345 (56.4)
No. NAC regimen (%)/745 pts:
MVAC 150 (23.4)
Gemcitabine/cisplatin 371 (57.8)
Gemcitabine/carboplatin 48 (7.5)
Cisplatin/etoposide 21 (3.3)
Cisplatin 9 (1.4)
Other 43 (6.7)
Postop
No. pathological stage (%)/726 pts:
pT0 151 (24.3)
pTa-pT2 194 (31.2)
pT3-pT4 106 (17.0)
pTxNþ 171 (27.5)
Median No. lymph nodes removed (IQR)/745 pts 21 (12e39)
No. progression (%)/630 pts 166 (30.9)
No. dead at last followup (%)/754 pts 201 (30.8)p ¼ 0.01). Gender, Khorana score, NAC regimen and
pathological TNM stage did not differ significantly
between patients with and without TEE (table 1).
The preNAC Khorana risk score was 1 or 2 in 88%
of patients for whom it was available, indicating
intermediate TEE risk.
Mean overall survival in patients in whom TEE
did and did not develop was 43.4 (95% CI 31.5e55.2)
vs 68.7 months (95% CI 62.8e74.7, p ¼ 0.06). There
was also only a trend toward decreased cancer
specific survival (p ¼ 0.07). Development of a TEE
preoperatively was not significantly associated with
overall survival whereas a postoperative TEE that
occurred more than 30 days after RC was associated
with worse overall survival (p ¼ 0.03). On multi-
variable regression analysis a TEE was not signifi-
cantly associated with decreased overall survival
(table 2). However, pathological stage and a high
Khorana score were adverse risk factors for overall
survival.DISCUSSION
Our data clearly demonstrate that TEEs are com-
mon in patients with MIBC who undergo NAC fol-
lowed by RC with 58% of TEEs developing
preoperatively during or after NAC. To ourTEE p Value
105 e
67.6 (59.4e73.0) 0.02 (Wilcoxon rank sum test)
0.39 (Fisher exact test)
75 (71.4)
30 (28.6)
0.79 (Wilcoxon rank sum test)
58 (62.4)
22 (23.6)
11 (11.8)
2 (2.2)
25 (24) 0.02 (Fisher exact test)
10.9 (7.7e12.9) 0.01 (Wilcoxon rank sum test)
0.10 (Fisher exact test)
34 (34.7)
64 (65.3)
0.34 (Fisher exact test)
16 (15.5)
70 (68.0)
7 (6.8)
4 (3.9)
0
6 (5.8)
0.42 (Fisher exact test)
22 (21.4)
27 (26.0)
19 (18.3)
36 (34.6)
23 (14e40) 0.09 (Wilcoxon rank sum test)
40 (43.5) <0.001 (log rank test)
39 (38.6) 0.06 (log rank test)
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Figure 1. A, incidence of any TEE by institution and TEE type. Institution and total number of patients contributed by each institution
are listed in decreasing order of TEE incidence. Horizontal line indicates 13.8% incidence across all centers. B, TEE timing relative to RC
by center.McMaster, McMaster University. U Roch, University of Rochester. UTSW, University of Texas Southwestern Medical Center.
Vancouver PC, Vancouver Prostate Centre. NKI-AvL, Netherlands Cancer Institute-Antoni van Leuwenhoek Hospital. Helsinki, Helsinki
University Hospital. FCCC, Fox Chase Cancer Center. Turku, Turku University Hospital. McGill, McGill University.
1630 THROMBOEMBOLIC EVENTS AND UROTHELIAL CANCER OF BLADDERknowledge this is a novel observation because the
literature related to TEEs in patients with bladder
cancer has to date focused on those with metastatic
disease,10,14 those who receive primary chemo-
therapy15 or those undergoing RC.16,17 Studies of
the risk of TEE during NAC are currently lacking.
VanDlac et al reported a TEE rate of 6% in
American patients undergoing RC with a mean timefrom RC to TEE of 15.2 days.17 Risk factors were
age, operative time, sepsis and length of hospital
stay. Although the study did not factor in the po-
tential effect of NAC, the reported overall incidence
exactly mirrors our postoperative incidence of 6%.
Similarly, in a retrospective study of patients with
bladder cancer undergoing RC Sun et al reported a
post-RC symptomatic TEE incidence of 6.4% in a
Figure 2. Cumulative hazard plot shows TEE development vs
time from NAC start to TEE. University of Southern California-
Norris Comprehensive Cancer Center data are not shown as
data were unavailable on time from NAC start to RC in
patients without TEE. Censoring occurred 6 months after RC
(open circles) in patients without TEE. Median time from NAC
start to RC was 3.53 months (range 1.22 to 74.2).
THROMBOEMBOLIC EVENTS AND UROTHELIAL CANCER OF BLADDER 1631subgroup of 388 patients despite the use of unfrac-
tionated heparin prophylaxis.18 The most recent
AUA (American Urological Association) Best Prac-
tice Statement published in 2009 only addresses
venous thromboembolism prophylaxis during the
postoperative period19 and compliance with these
recommendations among AUA members is report-
edly low.20 Likewise, even with the use of throm-
boprophylaxis after RC a median TEE rate of 2.0%Table 2. Univariable and multivariable regression analyses
with respect to overall survival
Univariable Multivariable
HR (95% CI) p Value HR (95% CI) p Value
Age 1.02 (1.01e1.03) 0.004 1.01 (1.00e1.03) 0.15
TEE:
None Referent Referent
Any development 1.40 (0.99e1.97) 0.06 0.99 (0.67e1.45) 0.94
TNM pathological
stage:
pT0 Referent Referent
pTa-pT2 1.94 (1.10e3.41) 0.002 1.70 (0.95e3.05) 0.08
pT3-pT4 6.51 (3.80e11.18) <0.001 5.08 (2.85e9.04) <0.001
pTxNþ 10.25 (6.15e17.09) <0.001 8.46 (4.99e14.36) <0.001
Khorana score:
1 Referent Referent
2 1.46 (1.05e2.05) 0.03 1.36 (0.97e1.92) 0.08
3 1.63 (1.07e2.48) 0.02 1.11 (0.72e1.72) 0.63
4 4.20 (1.84e9.60) 0.001 5.56 (2.40e12.88) <0.001(range 0% to 6.4%) in the early postoperative period
was documented in our study. Importantly, TEEs
continued to develop even after 30 days following
RC, which is past the time of extended TEE pro-
phylaxis recommended in guidelines for patients
who undergo pelvic surgery for cancer.9
In patients with metastatic or locally advanced
solid tumors who are treated with chemotherapy
several placebo controlled studies have demon-
strated that pharmacological thromboprophylaxis
results in a statistically significant reduction in
TEEs without significantly increasing the risk of
bleeding.21e24 In contrast, other studies showed no
significant benefit.25 Currently, to our knowledge
there are no recommendations for routine outpa-
tient TEE prophylaxis in patients with cancer dur-
ing systemic chemotherapy but this is an active area
of research and recommendations may change.26
Notably, most of the aforementioned studies,
which were performed in different or diverse
advanced cancer populations and were not limited
to bladder cancer, demonstrated a 3.4% to 4.4% TEE
incidence in the placebo group.21e23,25 This rate is
remarkably lower than the 7.6% preoperative rate
in our study, suggesting that outpatients with
MIBC who undergo NAC are at high risk for TEE
and should be the subject of a trial to investigate
whether TEE prevention is justified. In patients
with pancreatic cancer, in whom the rate of TEE is
substantially higher, dalteparin has achieved an
85% risk reduction from a 23% TEE incidence rate
in patients who received gemcitabine alone to
3.4%.24 Risk reductions due to thromboprophylaxis
in the other studies range from 49% to 85%.21e23
While the overall risk of TEE in our patients un-
dergoing NAC followed by RC was 13.8%, repre-
senting 1 of 7 patients, we noted a wide and
statistically significant variation (5.4% to 32.1%) in
TEE incidence among the institutions. There are
several possible reasons for these large differences.
While TEE prophylaxis was not administered to any
patientsduringNAC, thedurationof theNACcourse,
the number of cycles and the regimens differed
among the institutions. Indeed, the duration of NAC
was significantly increased in patients with vs
without a TEE, potentially putting patients at higher
risk for TEE at centers where longer courses of NAC
are administered. A delay in NAC due to the devel-
opment of a TEE may also have caused the longer
duration but delays were not captured in our study.
Different NAC regimens could also account for
some of the differences, although we did not find a
statistically significant difference in regimens be-
tween patients in whom a TEE developed and those
in whom it did not. Nevertheless, in Helsinki and
Turku all patients except 1 were treated with
cisplatin/gemcitabine. At the other centers the
1632 THROMBOEMBOLIC EVENTS AND UROTHELIAL CANCER OF BLADDERregimens were more variable. While the type of
MVAC regimen (dose-dense vs regular) was infre-
quently recorded in our database, treatment with
dose-dense MVAC, for which the duration of
chemotherapy is generally shorter, may also explain
some differences, although a smaller percent of pa-
tients with a TEE were treated with MVAC (15.5%
vs 23.4%). In a recent analysis of SEER (Surveil-
lance, Epidemiology and End Results) data on stage
2-3 bladder cancer in patients older than 65 years
Gupta et al reported a 43% higher risk of TEE
within the first year in patients who received plat-
inum based chemotherapy compared to those who
did not receive it.15 Therefore, it is reasonable to
believe that platinum based NAC may potentiate
long-term thrombogenicity.
None of the current patients underwent routine
Doppler ultrasound to exclude DVT unless clinically
indicated. However, we suspect that different prac-
tices with respect to imaging performed for restaging
near the completion of NAC and before RC may ac-
count for the large differences in the preoperative
TEE incidence. For example, at McMaster Univer-
sity, where the largest number of preoperative TEEs
in general and PEs in particular was detected, CT
of the chest is often done routinely for restaging
following NAC. In a prospective analysis of 407
oncology patients who underwent CT chest imaging
for unrelated indications PE was found in up to 11%
who had recently received chemotherapy.27 The
detection of unsuspected PE on staging CT in pa-
tients with cancer may have an impact on survival
and complications that is similar to that of symp-
tomatic PE.28,29 O’Connell et al documented that in
patientswith cancer thefinding ofunsuspectedPEon
routine stagingCThadanegative impact on survival,
particularly if thePEwas locatedmoreproximal than
the subsegmental arterial branches.30
Because the use of restaging chest CT at the end
of NAC at most other centers participating in this
study was variable, we suspect that the incidence of
TEE may actually be higher than the overall 13.8%
rate reported. Given the high incidence of inciden-
tally detected PE during NAC in our study at
McMaster University12 and its significantassociation with adverse clinical outcomes,28e30
routine addition of the chest to the post-NAC
restaging abdominal and pelvic CT should be
considered. Since the incidence of silent DVTs in our
patient population is also unknown, the value of not
only routine restaging chest CT but also lower
extremity Doppler ultrasound would be best
addressed within the framework of a prospective
prevention trial. Moreover, since the use of antico-
agulants in patients with cancer treated with
chemotherapy has been shown to confer a tangible
survival benefit,26 consideration of a prospective
prevention trial of prophylaxis during the NAC
treatment period is warranted. Our data may assist
in planning such a trial. We also suggest that at the
end of NAC preoperative chest CT and lower ex-
tremity Doppler ultrasound imaging be incorpo-
rated into the protocol to maximize event detection.
This study has several limitations, most notably
its retrospective nature and the nonuniform use of
chest imaging and TEE prophylaxis, which varied
throughout the study duration at each institution.
Prophylaxis regimens to prevent TEEs within the
first month after RC are now mostly routine but
they were not used consistently or frequently at
many institutions during the early period of this
study. The comorbidities and disease characteristics
of these patients may be different than those in the
general patient population with MIBC, given the
referral nature of most participating institutions,
leading to an inflated TEE rate. There were some
missing data elements, particularly in the timing of
RC with respect to the start of NAC, which limited
the determination of risk factors for the develop-
ment of TEE. We also did not capture delays or dose
reductions in the administration of NAC.CONCLUSIONS
This multicenter retrospective study shows that
TEEs are common in patients with bladder cancer
who undergo neoadjuvant chemotherapy followed
by radical cystectomy. Further investigation is
warranted in a prospective trial testing thrombo-
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